Corrigendum: Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model
- 1BioSystems and Micromechanics IRG, Singapore-MIT Alliance for Research and Technology, Singapore, Singapore
- 2Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 3Singapore Immunology Network (SIgN), Biomedical Sciences Institute, Agency for Science, Technology, and Research, Singapore, Singapore
- 4Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research, Singapore, Singapore
- 5Programme of Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
- 6Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States
A corrigendum on
Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model
by Lee SWL, Adriani G, Ceccarello E, Pavesi A, Tan AT, Bertoletti A, et al. Front Immunol (2018) 9:416. doi: 10.3389/fimmu.2018.00416
In our original research article, there was an error in the Materials and Methods section, subsection 3D Microfluidic Co-Culture and Blocking Experiments, where it was written that 100 µg/mL of anti-PD-L1-blocking or anti-PD-1-blocking antibody or their respective isotype control was used. The correct concentration is 10 µg/mL. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
The original article has been updated.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: microfluidics, monocytes, T cell receptor-redirected T cells, immunotherapy, immune checkpoint, PD-L1, tumor microenvironment
Citation: Lee SWL, Adriani G, Ceccarello E, Pavesi A, Tan AT, Bertoletti A, Kamm RD and Wong SC (2018) Corrigendum: Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. Front. Immunol. 9:1719. doi: 10.3389/fimmu.2018.01719
Received: 12 June 2018; Accepted: 12 July 2018;
Published: 24 July 2018
Edited and Reviewed by: Vincenzo Bronte, Università degli Studi di Verona, Italy
Copyright: © 2018 Lee, Adriani, Ceccarello, Pavesi, Tan, Bertoletti, Kamm and Wong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
†These authors have contributed equally to this work.